home

clinical

therapeutic-glaucoma

Glaucoma

Articles

Pressure-dependent optic nerve disease, retinal disease.

The 2 faces of glaucoma

Michelessi is an investigator at the Glaucoma Research Unit of the IRCCS G. B. Bietti Foundation for Study and Research in Ophthalmology in Rome, Italy.

Giammaria is a research fellow in the Department of Ophthalmology and Visual Sciences at Dalhousie University in Halifax, Canada.

Two trials examine factors affecting the risk of disease.

Pivotal study data drive glaucoma patient treatment decisions 

MIGS drainage device offers hope for challenging cases.

Study: Lower IOP, medication burden in OAG patients

Exploring subtleties helps ophthalmologists understand postop surprises, drug reactions.

An eye toward plateau iris and its implications

Cheryl Guttman is a medical writer based in Deerfield, Ill.

Measurements from multiple studies show benefits of rho-kinase inhibition.

Research: Treatment targets steroid-induced OHT

Visible-light optical coherence tomography proves valuable in studies.

IPL offers glaucoma biomarker for early-stage disease

Fotis Topouzis, MD, PhD, is chair of the Department of Ophthalmology, Aristotle University of Thessaloniki, Greece, and current president of the European Glaucoma Society. He is principal investigator of two large population-based studies (Thessaloniki Eye Study, EUREYE Study). He reports grant support from Alcon, Bausch & Lomb, Bayer, Novartis, Pfizer, and Thea, and personal fees from Alcon, Allergan, Bayer, Novartis, Omikron, Pfizer, Santen, and Thea.

Dimitrios Giannoulis, MD, is university associate in the 1st Department of Ophthalmology at Aristotle University of Thessaloniki, Greece. He has no financial disclosures to report.

Details enhance knowledge of biological pathways that contribute to disease pathogenesis.

Unraveling the genetics of glaucoma

Therapeutic Glaucoma

Mark Gallardo, MD, reports 12-month outcomes of iStent inject® combined with cataract surgery in a predominantly Hispanic patient population with mild to moderate open-angle glaucoma (OAG) and comorbid cataract.

Micro-bypass stent implant during cataract surgery: lower IOP, fewer medications

Basil Williams, Jr., MD, reports on the association between development of elevated intraocular pressure and numerous commonly performed vitreoretinal treatments. 

Factors to consider in IOP elevations associated with vitreoretinal treatments

Sunaric-Mégevand is medical director of the Florissant Eye Centre and director of the Eye Research Centre at Adolphe de Rothschild Hospital in Geneva, Switzerland.



Bron is a professor of ophthalmology and head of the glaucoma unit at the University Hospital in Dijon, France. He acts as a consultant for Aerie, Allergan, Bausch + Lomb, Santen, and Théa.



Although minimally invasive procedure gives hope, additional research is required.